TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04739813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study: NCT05499221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carriere motion appliance
Description: The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere motion appliance
Description: The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
Study: NCT04739813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
Study: NCT04508699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semantic learning
Description: Experimental semantic learning from linguistic context task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: semantic learning
Description: Experimental semantic learning from linguistic context task
Study: NCT06626412

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Test: 18F-SynVesT-1 PET
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: 18F-SynVesT-1 PET
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric MRI
Description: Magnetic resonance imaging of brain volume.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volumetric MRI
Description: Magnetic resonance imaging of brain volume.
Study: NCT06685861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a digital product based on CBT
Description: The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
Study: NCT04981678

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Patients randomized to this group will reduce their buprenorphine dose prior to surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
Study: NCT06720051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraosseous dexamethasone injection after 3rd molar surgery
Description: In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucosal dexamethasone injection after 3rd molar surgery
Description: In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
Study: NCT06716034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Plan and Support
Description: The intervention is a virtually-delivered, personalized nutrition plan and support to improve dietary intake of healthy food (fruit, vegetables and whole grains), based on the principles of a Mediterranean-style diet. Components of the intervention include nutrition counselling, menu planning and the provision of groceries, delivered biweekly, face-to-face, by a registered dietitian over 8 weeks, using a virtual platform. The nutrition counselling structure is grounded in evidence-based behaviour change theory for dietary interventions. Youth and parents will co-develop a personalized menu plan. In addition to biweekly nutrition counselling, participants will receive a food pantry basket, and weekly grocery deliveries to support the menu plan.
Study: NCT06724068

Intervention type: OTHER
Intervention: Diabetes，Insulin resistance，Control
Description: This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022

Intervention type: OTHER
Intervention: Diabetes，Insulin resistance，Control
Description: This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022

Intervention type: OTHER
Intervention: Diabetes，Insulin resistance，Control
Description: This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
Study: NCT06723587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instep weights use
Description: Players will perform their scheduled training sessions while wearing a 150-gram instep weight. The use of instep weights in the intervention group will be introduced progressively and gradually, increasing both the frequency of sessions and the duration of their use.~During weeks 1-2, instep weights will be used in one training session per week. During weeks 3-5, will be used in two training sessions per week.~And during weeks 6-8, will be used in three training sessions per week.~The duration of instep weight usage within each session will increase by 5% weekly, starting at 40% in Week 1 and reaching 75% by Week 8.
Study: NCT06722482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA
Description: Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
Study: NCT06288165

Intervention type: DEVICE
Intervention: Coronary Sinus Reducer Implantation
Description: Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
Study: NCT04927754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral guidance
Description: Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
Study: NCT06722482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CEBX
Description: Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
Study: NCT06722846

Intervention type: BEHAVIORAL
Intervention: Randomized Case Vignette Study
Description: Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.
Study: NCT05422274

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
Study: NCT06724900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB304
Description: Genetically modified herpes simplex type 1 virus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (NS)
Description: Placebo
Study: NCT06732570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity laser
Description: the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
Study: NCT06733727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
Study: NCT06733662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Education-based motivational interviewing Group
Description: The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
Study: NCT06733389

Intervention type: OTHER
Intervention: peripheral waveform collection
Description: The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
Study: NCT06731907

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV Infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100mg/m\^2 IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m\^2 IV infusion.
Study: NCT05865574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706 Injection
Description: 1 vial/carton, 400 mg/16 mL/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT1706 Injection
Description: 1 vial/carton, 400 mg/16 mL/vial
Study: NCT05028556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 of Y101D
Description: Y101D, 1mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 of Y101D
Description: Y101D, 3mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 of Y101D
Description: Y101D, 10mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 of Y101D
Description: Y101D, 20mg/kg, Q2W, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 of Y101D
Description: Y101D, 30mg/kg, Q2W, intravenous infusion
Study: NCT05511701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Care Model
Description: The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is \> 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Model
Description: All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is \> 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
Study: NCT06499454

Intervention type: DIAGNOSTIC_TEST
Intervention: Ruby ROSE evaluation
Description: Creation and digitization of ROSE slides produced using Ruby's instrument from bronchoscopic biopsy samples
Study: NCT06731907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: HER3-Dxd 5.6mg/kg IV infusion.
Study: NCT06732245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931, an oral, daily~• A quadruple receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA-931
Description: NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA-931 150 mg + no Tirzepatide
Description: NA-931 150 mg + no Tirzepatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA-931
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study: NCT06733974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted Intervention
Description: The participant, i.e. relative, will receive the multifaceted intervention which include: a first meeting with the healthcare team including written information about palliative care for dying patients, information on possibility to participate in care, pro-active communication, and dedicated interview and brochure after the patient's death with possibility of psychological follow up.
Study: NCT06732024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaccum assisted closure
Description: close skin and SC tissue by vaccum device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary wound closure
Description: close skin and SC tissue by primary closure
Study: NCT06733883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: Music therapy
Study: NCT05451251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Implantation of deep brain stimulation lead within the pontine lesion
Study: NCT06388694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Care
Description: Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Physician Care
Description: Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
Study: NCT04998617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with curcumin
Description: Subjects will be given toothpaste to be used during this study with 0.5% curcumin
Study: NCT05559034

Intervention type: BEHAVIORAL
Intervention: Cognitive intervention
Description: This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
Study: NCT03728829

Intervention type: DRUG
Intervention: Trastuzumab+TP
Description: Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).